Skip to main content

DSGN

Stock
Health Care
Biotechnology

Performance overview

DSGN Price
Price Chart

Forward-looking statistics

Beta
1.12
Risk
89.93%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Company info

SectorHealth Care
IndustryBiotechnology
Employees93
Market cap$217.5M

Fundamentals

Enterprise value-$36.2M
Revenue$0.0
Revenue per employee
Profit margin0.00%
Debt to equity0.94

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$0.99
Dividend per share
Revenue per share
Avg trading volume (30 day)$380K
Avg trading volume (10 day)$402K
Put-call ratio

Macro factor sensitivity

Growth+3.7
Credit+3.1
Liquidity+0.3
Inflation-1.4
Commodities-0.8
Interest Rates-1.3

Valuation

Dividend yield0.00%
PEG Ratio-3.12
Price to sales
P/E Ratio-3.12
Enterprise Value to Revenue
Price to book0.94

Upcoming events

Next earnings dayMay 8, 2025
Next dividend day
Ex. dividend day

News

Wall Street Analysts See a 31.33% Upside in Design Therapeutics (DSGN): Can the Stock Really Move This High?

The consensus price target hints at a 31.3% upside potential for Design Therapeutics (DSGN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks Investment Research (March 12, 2025)
Design Therapeutics Shares Fall As Goldman Sachs Initiates With Sell Rating

Goldman Sachs initiated coverage of Design Therapeutics Inc (NASDAQ: DSGN) with a Sell rating and a $10 price target.  The analyst Madhu Kumar has caution about the Company's lead indication of Friedreich ataxia.

Benzinga (January 19, 2022)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free